Loading...
XNASSRTS
Market cap117mUSD
Dec 24, Last price  
7.14USD
1D
3.93%
1Q
28.88%
Jan 2017
36.00%
IPO
12.97%
Name

Sensus Healthcare Inc

Chart & Performance

D1W1MN
XNAS:SRTS chart
P/E
241.29
P/S
4.80
EPS
0.03
Div Yield, %
0.00%
Shrs. gr., 5y
2.88%
Rev. gr., 5y
-1.58%
Revenues
24m
-45.20%
10,478,9205,810,20510,273,09414,811,17520,587,82726,427,19027,263,2489,576,93227,042,00044,532,00024,405,000
Net income
485k
-98.00%
107,627-3,699,470-237,267-346,448-3,710,514-2,022,761-1,154,286-4,715,3134,119,00024,244,000485,000
CFO
-2m
L+51.91%
255,935-128,693-1,867,682-1,339,343-851,024-3,056,606-8,563,731-2,106,642-434,180-286,000-1,412,000-2,145,000
Earnings
Feb 06, 2025

Profile

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
IPO date
Jun 03, 2016
Employees
42
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
24,405
-45.20%
44,532
64.68%
27,042
182.37%
Cost of revenue
24,787
29,701
22,922
Unusual Expense (Income)
NOPBT
(382)
14,831
4,120
NOPBT Margin
33.30%
15.24%
Operating Taxes
167
3,746
(613)
Tax Rate
25.26%
NOPAT
(549)
11,085
4,733
Net income
485
-98.00%
24,244
488.59%
4,119
-187.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
(27)
(2,268)
(15)
BB yield
0.07%
1.84%
0.01%
Debt
Debt current
374
190
225
Long-term debt
1,379
1,850
174
Deferred revenue
60
139
262
Other long-term liabilities
(12)
Net debt
(21,395)
(23,480)
(14,120)
Cash flow
Cash from operating activities
(2,145)
(1,412)
(286)
CAPEX
(229)
(159)
(128)
Cash from investing activities
(187)
14,841
129
Cash from financing activities
(40)
(2,428)
(231)
FCF
(2,445)
926
1,114
Balance
Cash
23,148
25,520
14,519
Long term investments
Excess cash
21,928
23,293
13,167
Stockholders' equity
6,956
6,471
(17,775)
Invested Capital
42,916
41,855
44,277
ROIC
25.74%
10.53%
ROCE
30.68%
15.55%
EV
Common stock shares outstanding
16,266
16,618
16,503
Price
2.36
-68.19%
7.42
2.77%
7.22
87.05%
Market cap
38,388
-68.87%
123,307
3.49%
119,153
87.83%
EV
16,993
99,827
105,033
EBITDA
79
15,146
4,733
EV/EBITDA
215.10
6.59
22.19
Interest
2
1,000
Interest/NOPBT
0.01%
0.02%